Abstract
We carried out a multicentric retrospective study on cetuximab + chemotherapy in pre-treated refractory patients outside clinical protocols, by registering the main clinical and pathological parameters. We evaluated 144 pre-treated patients. Cetuximab was administered usually in combination with irinotecan (93.8%). A 45% disease control rate (complete plus partial responses plus stable disease) was obtained in 55 patients and was related to absence of weight loss (p<0.0001) and high grade (≥2) skin toxicity (p<0.0001). Median time to progression (TTP) was 4 months (95%CI 2.7-5.3) and median overall survival (OS) was 11.8 months (95%CI 8.5-15.1). Performance status ≤1, no weight loss and high grade (≥2) skin toxicity were related both to a longer TTP (p=0.035, p=0.035, p=0.0017) and OS (p<0.0001, p<0.0001, p=0.006). According to multivariate analysis, the absence of weight loss was related to longer TTP (HR 0.331, p=0.004) and OS (HR 0.176, p<0.0001), and EGFR over-expression (3+) to longer TTP (HR 0.402, p=0.020).
| Original language | English |
|---|---|
| Pages (from-to) | 374-379 |
| Number of pages | 6 |
| Journal | Journal of Chemotherapy |
| Volume | 20 |
| Issue number | 3 |
| Publication status | Published - Jun 2008 |
Fingerprint
Keywords
- Appropriate prescriptions
- Clinical outcome
- Multicenter study
- Palliative treatment
- Retrospective study
- Targeted therapies
ASJC Scopus subject areas
- Pharmacology (medical)
- Microbiology (medical)
Cite this
The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer : Outcome study in clinical practice. / Lelli, G.; Cataldo, S.; Carandina, I.; Urbini, B.; Bonetti, F.; Marzola, M.; Biasco, G.; Pantaleo, M. A.; Brandes, A.; Calandri, C.; Ravaioli, E.; Nanni, O.; Boni, C.; Banzi, C.; Negri, F.; Panetta, A.; Di Fabio, F.; Turci, D.
In: Journal of Chemotherapy, Vol. 20, No. 3, 06.2008, p. 374-379.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer
T2 - Outcome study in clinical practice
AU - Lelli, G.
AU - Cataldo, S.
AU - Carandina, I.
AU - Urbini, B.
AU - Bonetti, F.
AU - Marzola, M.
AU - Biasco, G.
AU - Pantaleo, M. A.
AU - Brandes, A.
AU - Calandri, C.
AU - Ravaioli, E.
AU - Nanni, O.
AU - Boni, C.
AU - Banzi, C.
AU - Negri, F.
AU - Panetta, A.
AU - Di Fabio, F.
AU - Turci, D.
PY - 2008/6
Y1 - 2008/6
N2 - We carried out a multicentric retrospective study on cetuximab + chemotherapy in pre-treated refractory patients outside clinical protocols, by registering the main clinical and pathological parameters. We evaluated 144 pre-treated patients. Cetuximab was administered usually in combination with irinotecan (93.8%). A 45% disease control rate (complete plus partial responses plus stable disease) was obtained in 55 patients and was related to absence of weight loss (p<0.0001) and high grade (≥2) skin toxicity (p<0.0001). Median time to progression (TTP) was 4 months (95%CI 2.7-5.3) and median overall survival (OS) was 11.8 months (95%CI 8.5-15.1). Performance status ≤1, no weight loss and high grade (≥2) skin toxicity were related both to a longer TTP (p=0.035, p=0.035, p=0.0017) and OS (p<0.0001, p<0.0001, p=0.006). According to multivariate analysis, the absence of weight loss was related to longer TTP (HR 0.331, p=0.004) and OS (HR 0.176, p<0.0001), and EGFR over-expression (3+) to longer TTP (HR 0.402, p=0.020).
AB - We carried out a multicentric retrospective study on cetuximab + chemotherapy in pre-treated refractory patients outside clinical protocols, by registering the main clinical and pathological parameters. We evaluated 144 pre-treated patients. Cetuximab was administered usually in combination with irinotecan (93.8%). A 45% disease control rate (complete plus partial responses plus stable disease) was obtained in 55 patients and was related to absence of weight loss (p<0.0001) and high grade (≥2) skin toxicity (p<0.0001). Median time to progression (TTP) was 4 months (95%CI 2.7-5.3) and median overall survival (OS) was 11.8 months (95%CI 8.5-15.1). Performance status ≤1, no weight loss and high grade (≥2) skin toxicity were related both to a longer TTP (p=0.035, p=0.035, p=0.0017) and OS (p<0.0001, p<0.0001, p=0.006). According to multivariate analysis, the absence of weight loss was related to longer TTP (HR 0.331, p=0.004) and OS (HR 0.176, p<0.0001), and EGFR over-expression (3+) to longer TTP (HR 0.402, p=0.020).
KW - Appropriate prescriptions
KW - Clinical outcome
KW - Multicenter study
KW - Palliative treatment
KW - Retrospective study
KW - Targeted therapies
UR - http://www.scopus.com/inward/record.url?scp=47349115226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=47349115226&partnerID=8YFLogxK
M3 - Article
C2 - 18606595
AN - SCOPUS:47349115226
VL - 20
SP - 374
EP - 379
JO - Journal of Chemotherapy
JF - Journal of Chemotherapy
SN - 1120-009X
IS - 3
ER -